Proteome Sciences PLC Director/PDMR Shareholding (4665D)
10 October 2018 - 1:28AM
UK Regulatory
TIDMPRM
RNS Number : 4665D
Proteome Sciences PLC
09 October 2018
9 October 2018
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences
Fund ("Vulpes") on 9 October 2018 that on the 5 and 8 October 2018
it purchased 54,000 and 460,899 Ordinary Shares of 1p,
respectively, in the capital of the Company ("Ordinary Shares") at
3.60p per Ordinary Share (the "Purchase"). Following the purchase,
Vulpes has a total direct and indirect interest in 60,851,987
equivalent to 20.62% of Proteome Sciences' total issued share
capital.
The Company would also like to announce that by virtue of Martin
Diggle being a Director of both Vulpes Investment Management and
the Company, he now has an interest in 60,851,987 Ordinary Shares
of the Company representing 20.62% of the issued share capital of
the Company.
The below notification is made in accordance with the
requirements of the EU Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Martin Diggle
----------------------------------------- --------------------------------
Reason for the notification
---------------------------------------------------------------------------
a) Position/status: Non-Executive Director
----------------------------------------- --------------------------------
b) Initial notification/Amendment: Initial Notification
----------------------------------------- --------------------------------
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name: Proteome Sciences Plc
----------------------------------------- --------------------------------
b) LEI: 213800Q62ICXANKU2986
----------------------------------------- --------------------------------
Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary Shares of 1p nominal
type of instrument: value
Identification code: GB0003104196
----------------------------------------- --------------------------------
b) Nature of the transaction: Purchase of Ordinary Shares
----------------------------------------- --------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
3.60 514,899
----------
----------------------------------------- --------------------------------
d) Aggregated information: Single transaction as in
* Aggregated volume: 4 c) above Average Volume(s)
Price
3.60 54,000
* Price: ----------
3.60 460,899
----------
----------------------------------------- --------------------------------
e) Date of the transaction: 5 October 2018 and 8 October
2018 respectively
----------------------------------------- --------------------------------
f) Place of the transaction: London Stock Exchange,
AIM (XLON)
----------------------------------------- --------------------------------
For further information:
Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Tel: +44 (0)20 7043 2116
Officer
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial
Officer
finnCap Limited (Nominated Adviser & Broker)
Geoff Nash/Hannah Boros (Corporate Tel: +44 (0)20 7220 0500
Finance)
Tim Redfern (Broking)
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering
high sensitivity, proprietary technologies and workflows for
mapping cell signalling pathways (SysQuant(R) ) and for the
discovery, validation and assay development of protein biomarkers
(TMTcalibrator(TM) ). The company has its headquarters in London,
UK, with laboratory facilities in Frankfurt, Germany from where the
PS Biomarker Services(TM) division provides outsourced proteomics
services and proprietary biomarker assays to biopharmaceutical and
diagnostics companies and to academia.
Proteome Sciences has patented several novel protein biomarkers
for diagnostic and treatment applications in important areas of
human therapeutics such as cancer, stroke and Alzheimer's disease,
and these are available for license.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFSIFLUFASEES
(END) Dow Jones Newswires
October 09, 2018 10:28 ET (14:28 GMT)
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From Apr 2024 to May 2024
Proteome Sciences (LSE:PRM)
Historical Stock Chart
From May 2023 to May 2024